# To Demonstrate the Non-inferiority of Eyestil Protection® Compared to Vismed® in Terms of Clinical Performance

> **NCT03803722** · NA · TERMINATED · sponsor: **SIFI SpA** · enrollment: 21 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DEVICE:** Eyestil Protection® unidose

## Key facts

- **NCT ID:** NCT03803722
- **Lead sponsor:** SIFI SpA
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-08
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Slow enrolment process and COVID situation worsened the situation. SIFI has developed a new product with probably a better performance. SIFI changed its marketing strategy and decided that Eyestil® Protection will be not marketed anymore
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03803722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03803722, "To Demonstrate the Non-inferiority of Eyestil Protection® Compared to Vismed® in Terms of Clinical Performance". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03803722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*